Title: IL-15Rα expression in inflammatory bowel disease patients before and after normalization of inflammation with infliximab
Authors: Perrier, Clementine * ×
Arijs, Ingrid *
Staelens, Dominiek
Breynaert, Christine
Cleynen, Isabelle
Covens, Kris
Ferrante, Marc
Van Assche, Gert
Vermeire, Severine
De Hertogh, Gert
Schuit, Frans
Rutgeerts, Paul
Ceuppens, Jan #
Issue Date: Jan-2013
Publisher: Blackwell Scientific Publications
Series Title: Immunology vol:138 issue:1 pages:47-56
Article number: 10.1111/imm.12014
Abstract: Interleukin-15 (IL-15) is a pro-inflammatory cytokine suspected to contribute to the inflammation in inflammatory bowel diseases (IBD). The specific receptor chain IL-15Rα can be expressed as a transmembranous signaling receptor, or can be cleaved by a disintegrin and metalloprotease domain 17 (ADAM17) into a neutralizing, soluble receptor (sIL-15Rα). The aim of this study is to evaluate the expression of IL-15Rα in ulcerative colitis (UC) and Crohn's disease (CD) patients before and after infliximab (IFX) therapy. Gene expression of IL-15Rα, IL-15 and ADAM17 was measured at the mRNA level by quantitative reverse transcriptase PCR in mucosal biopsies harvested before and after first IFX therapy. Concentrations of sIL-15Rα were measured in sera of patients by ELISA and IL-15Rα protein was localized in the gut by immunohistochemistry and immunofluorescence. Mucosal expression of IL-15Rα is increased in UC and CD patients as compared to controls and it remains elevated after IFX therapy in both responder and non-responder patients. The concentration of sIL-15Rα in serum is also increased in UC patients when compared to controls and does not differ between responders and non-responders both before and after IFX. CD patients have levels of sIL-15Rα comparable to healthy controls before and after therapy. In mucosal tissues, IL-15Rα+ cells closely resemble activated memory B cells with a preplasmablastic phenotype. To conclude, IBD patients have an increased expression of IL-15Rα mRNA in the mucosa. Expression is localized in B cells, suggesting that IL-15 regulates B cell functions during bowel inflammation. No change in release of sIL-15Rα is observed in patients treated with IFX. © 2012 The Authors. Immunology © 2012 Blackwell Publishing Ltd.
ISSN: 0019-2805
Publication status: published
KU Leuven publication type: IT
Appears in Collections:Translational Cell & Tissue Research
Translational Research in GastroIntestinal Disorders
Laboratory of Clinical Immunology
* (joint) first author
× corresponding author
# (joint) last author

Files in This Item:

There are no files associated with this item.

Request a copy


All items in Lirias are protected by copyright, with all rights reserved.

© Web of science